Insulet Corp (PODD) stock analysis
Insulet Corp (PODD) clears 4 of this site's 8 mechanical value filters, 5 of 8 Buffett-style checks and 2 of 5 Lynch-style checks. At $148.12 it trades 117.0% above this site's neutral DCF value (a margin of safety of -117.0%). Its earnings quality rates Strong and it returns 0.0% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does Insulet do?
Insulet makes the Omnipod, a tubeless insulin pump worn on the body that delivers insulin for people with diabetes.
What stands out about Insulet?
- The share price implies 28.0% yearly growth. At $148.12, PODD's free cash flow of $4.00 per share would have to grow 28.0% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
- Misses 2 of the 8 value filters. It fails Market Cap > $25B ($9.8B) and Trailing P/E < 25 (26.22); the other 4 pass and 2 were not evaluated. See every filter.
- Strongest against peers: revenue growth. At 29.4% (peer median 8.6%) it ranks 1st of 34 among health care stocks this site tracks. See the ranking.
- Weakest against peers: free-cash-flow yield. At 2.7% (peer median 5.5%) it ranks 32nd of 34 among health care stocks this site tracks. See the ranking.
- Insiders have been buying. 1 open-market purchase was reported in SEC Form 4 filings in the last 90 days, about $3.5 million in all. See the Insider Buying Tracker.
How has Insulet's share price moved?
The interactive price chart needs JavaScript.
Is Insulet undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -117.0%
- P/E vs. its own history 26.2x · at/below its cheapest point Real range: 45.2x–3868.3x over 5 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Buy · 3.88/5 32 analysts this month: 9 strong buy, 10 buy, 13 hold, 0 sell, 0 strong sell (Finnhub).
- Altman Z″-Score (bankruptcy risk) 4.78 · Safe zone
- Earnings quality (is the profit real?) Strong · all 5 checks clean accruals −10.3% of assets · 131% of profit arrived as cash · stock comp 2.3% of revenue · share count −1.2% a year. From the latest 10-K (year to Dec 2025) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) 0.0% net Latest fiscal year (2025): dividends 0.0% + buybacks 0.6% − stock comp 0.6%, as a share of today's market cap. Stock comp outruns what comes back in cash. Over 14 years its split-adjusted share count rose 52%. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) $5.99 per $1 of new profit · Capital-hungry · but only 15% return on capital Operating profit $3M → $334M, capital needed $210M → $2.2B, 2016–2025 (3-year averages); return on capital now 15% before tax. Buffett's See's Candies needed $0.42 per $1 of new profit, FlightSafety $3.20, a typical grower about $5. See Capital-Light Compounders.
- PEG (growth at a reasonable price) 1.12 · Above fair P/E 26.2× ÷ 23.4% a year of growth behind it. 111th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 2 of 4 · misses capital-light, cash back Capital-light growth: not cleared (only 15% return on capital); Profit is real: cleared; Cash to owners: not cleared (−0.4% a year net); Fair price (PEG): cleared. See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 2 flags
- Standing vs. sector peers 4 of 6 measures above the median Compared with the 33 other health care stocks this site tracks: 1 in the top third, 1 in the bottom third.
How does Insulet compare with its peers?
4 of 6 measures sit above the median of the 33 other health care stocks tracked here, 1 in the top third and 1 in the bottom third.
- P/E ratiolower is cheaper · peer median 24.6× 26.2× –19th of 32
- Free-cash-flow yieldhigher is cheaper · peer median 5.5% 2.7% ✕32nd of 34
- Return on equityhigher is better · peer median 15% 17% –12th of 34
- Net marginhigher is better · peer median 9.3% 12.3% –13th of 34
- Revenue growthhigher is better, year on year · peer median 8.6% 29.4% ✓1st of 34
- Debt / equitylower is safer · peer median 0.69 0.63 –14th of 34
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and PODD doesn't clear enough of it yet. In its favor: PODD is currently earning a strong return on shareholders' equity, and has kept that profitability up over five years, not just this year, converts sales into profit at healthy margins, has grown earnings per share at a solid clip over five years, and earns many times its interest expense, so debt service isn't a worry. Where it comes up short: PODD carries more debt relative to equity than he typically tolerates, is trading above what a conservative discounted-cash-flow estimate says it's worth right now, and trades rich relative to owner earnings, the real cash the business could pay out.
- ROE (TTM) > 11% ✓
- ROE (5yr avg) > 11% ✓
- Debt/Equity < 0.5 ✕
- Pretax margin > 15% ✓
- EPS growth (5yr) > 7% ✓
- Interest coverage > 5x ✓
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✕
- Bonus: returning capital via buybacks FY2025
Lynch looked for growth stories that weren't overpriced for that growth, and PODD falls short of his bar. In its favor: PODD isn't asking too much even by a fast grower's usual richer multiple, and is generating real cash to back up a fast grower's higher price tag. Where it comes up short: PODD doesn't clear the tighter PEG bar a fast grower needs to justify its pace, is growing earnings outside the 20-50% band he considered sustainable for a fast grower - either not fast enough to earn the label, or a pace he'd flag as unlikely to hold up, and is leaning on more debt than he liked a growth story to carry.
- PEG < 1 (stricter for fast growers) ✕
- EPS growth 20%-50% ✕
- Debt/Equity < 0.5 ✕
- P/E < 40 ✓
- Price/FCF < 40 ✓
- Bonus: insiders buying (90d) 1 buy, ~$3.5M
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does Insulet pass?
- Market Cap > $25B $9.8B
- Trailing P/E < 25 26.22
- PEG Ratio < 1.5 1.12
- Price/Book < 8 6.50
- Price/Sales < 7 3.22
- EPS Growth YoY > -5% +329.8%
- vs 50-day MA (±12%) Not evaluated †
- vs 200-day MA (±12%) Not evaluated †
What is Insulet's margin of safety?
History tracking starts this week - check back in a future week to see how this has moved.
Where is Insulet in its 52-week range?
What is the short interest in Insulet?
5,357,802 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with Insulet? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case -28%
- Short interest under 5% of float 7.8%
- Passes most of the 6 fundamental filters 4/6 passed
- Price run-up backed by value, not just momentum +13% off 52wk low
- Debt/equity stable since 2016 5.27 → 0.63
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have Insulet shareholders gained per year?
Earnings growth per share plus dividend.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from PODD's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do Insulet's 10-year financials show?
From PODD's own 10-K filings (SEC EDGAR): up to the last 10 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about Insulet
What kind of company is Insulet?
Insulet makes the Omnipod, a tubeless insulin pump worn on the body that delivers insulin for people with diabetes. This site groups it with Health Care stocks.
Is Insulet trading above or below its DCF value?
At $148.12, PODD trades 117.0% above this site's neutral DCF value of $68.26 per share, a margin of safety of −117.0%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does Insulet pass?
PODD passes 4 of 8. It passes PEG Ratio < 1.5 (1.12), Price/Book < 8 (6.50), Price/Sales < 7 (3.22) and EPS Growth YoY > -5% (+329.8%). It misses Market Cap > $25B ($9.8B) and Trailing P/E < 25 (26.22). vs 50-day MA (±12%) and vs 200-day MA (±12%) were not evaluated, because the moving-average checks only run on stocks that clear the fundamentals first. The 8-filter list shows every stock that passes all of them.
Are Insulet's insiders buying its shares?
Yes: 1 open-market insider purchase of Insulet shares, worth about $3.5 million in total, was reported in SEC Form 4 filings in the 90 days up to this page's last update. Only open-market purchases count here, not option exercises or stock awards. See the Insider Buying Tracker.
When does Insulet report earnings next?
Insulet's next earnings report is expected on November 4, 2026, with analysts expecting earnings of $1.62 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 4 times, by an average of +9.8%.
How heavily is Insulet stock sold short?
As of September 30, 2026, 7.8% of PODD's float was sold short (5,357,802 shares, 3.9 days to cover), up 5.4% from the prior reporting period. FINRA publishes short interest twice a month, so it changes about every two weeks; this site flags anything above 5% of the float.
Where do these numbers come from?
- Financial statements: Insulet's 10-K annual report for the year ended Dec 31, 2025, filed Feb 18, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this Insulet Corp analysis
This page shows every value-investing check the site runs on Insulet Corp (PODD) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.